Quick Takeaways
- ORBIMED ADVISORS LLC filed SCHEDULE 13G/A for RAPT Therapeutics, Inc. Common Stock, par value $0.0001 per share (RAPT).
- Disclosed ownership: 6.6%.
- Date of event: 30 Sep 2025.
ORBIMED ADVISORS LLC - 30 Sep 2025 SCHEDULE 13G/A Report for RAPT Therapeutics, Inc. Common Stock, par value $0.0001 per share (RAPT)
- Filing Manager
- ORBIMED ADVISORS LLC
- Reporting Manager
- ORBIMED ADVISORS LLC
- Symbol
- RAPT
- Shares outstanding
- 16,463,909 shares
- Disclosed Ownership
- 1,086,618 shares
- Ownership
- 6.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Nov 2025, 18:18:35 UTC
- Date of event
- 30 Sep 2025
- Previous filing
- 14 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"ORBIMED ADVISORS LLC disclosed 6.6% ownership in RAPT Therapeutics, Inc. Common Stock, par value $0.0001 per share (RAPT) on 30 Sep 2025."
What Changed
- Previous schedule filing date: 14 Feb 2025.
- Current filing was accepted on 14 Nov 2025, 18:18.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 6.6% | 1,086,618 | 0 | 1,086,618 | /s/ Carl L. Gordon | Carl L. Gordon/Member |